Advanced search
Publication Cover
Leukemia & Lymphoma Volume 63, 2022 - Issue 3
Submit an article Journal homepage
340
Views
0
CrossRef citations to date
0
Altmetric
Original Articles

Value of measurable residual disease monitoring in patients with acute promyelocytic leukemia in the era of frontline ‘chemotherapy-free’ therapy

Jorge M. Ramos Pereza Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USAView further author information
,
Keyur P. Patelb Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, United StatesView further author information
,
Sanam Loghavib Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, United StatesView further author information
,
Guillermo Garcia-Maneroa Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USAView further author information
,
Gautam Borthakura Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USAORCID Iconhttps://orcid.org/0000-0001-7679-6453View further author information
ORCID Icon,
Elias Jabboura Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USAView further author information
,
William Wierdaa Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USAView further author information
,
Sherry Piercea Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USAView further author information
,
Mark Brandta Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USAView further author information
,
Steven Kornblaua Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USAView further author information
,
Tapan Kadiaa Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USAView further author information
,
Naval Davera Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USAView further author information
,
Courtney D. DiNardoa Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USAView further author information
,
Nitin Jaina Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USAView further author information
,
Musa Yilmaza Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USAView further author information
,
Nicholas Shorta Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USAView further author information
,
Srdan Verstovseka Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USAORCID Iconhttps://orcid.org/0000-0002-6912-8569View further author information
ORCID Icon,
Alessandra Ferrajolia Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USAView further author information
,
Michael Andreeffa Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USAView further author information
,
Marina Konoplevaa Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USAView further author information
,
Daniel Riveraa Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USAView further author information
,
David McCuea Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USAView further author information
,
Hagop M. Kantarjiana Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USAView further author information
&
Farhad Ravandia Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USACorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0002-7621-377XView further author information
ORCID Icon show all
Pages 672-675 | Received 29 Jun 2021, Accepted 06 Oct 2021, Published online: 20 Oct 2021

References

  • Rowley JD, Golomb HM, Dougherty C. 15/17 Translocation, a consistent chromosomal change in acute promyelocytic leukaemia. Lancet. 1977;1(8010):549–550.
  • Grignani F, Ferrucci PF, Testa U, et al. The acute promyelocytic leukemia-specific PML-RAR alpha fusion protein inhibits differentiation and promotes survival of myeloid precursor cells. Cell. 1993;74(3):423–431.
  • Miller WH, Levine K, DeBlasio A, Jr, et al. Detection of minimal residual disease in acute promyelocytic leukemia by a reverse transcription polymerase chain reaction assay for the PML/RAR-alpha fusion mRNA. Blood. 1993;82(6):1689–1694.
  • Huang W, Sun GL, Li XS, et al. Acute promyelocytic leukemia: clinical relevance of two major PML-RAR alpha isoforms and detection of minimal residual disease by retrotranscriptase/polymerase chain reaction to predict relapse. Blood. 1993;82(4):1264–1269.
  • Lo Coco F, Diverio D, Pandolfi PP, et al. Molecular evaluation of residual disease as a predictor of relapse in acute promyelocytic leukaemia. Lancet. 1992;340(8833):1437–1438.
  • Grimwade D, Jovanovic JV, Hills RK, et al. Prospective minimal residual disease monitoring to predict relapse of acute promyelocytic leukemia and to direct pre-emptive arsenic trioxide therapy. J Clin Oncol. 2009;27(22):3650–3658.
  • Lo-Coco F, Avvisati G, Vignetti M, et al. Retinoic acid and arsenic trioxide for acute promyelocytic leukemia. N Engl J Med. 2013;369(2):111–121.
  • Burnett AK, Russell NH, Hills RK, et al. Arsenic trioxide and all-trans retinoic acid treatment for acute promyelocytic leukaemia in all risk groups (AML17): results of a randomised, controlled, phase 3 trial. Lancet Oncol. 2015;16(13):1295–1305.
  • Ravandi F, Estey E, Jones D, et al. Effective treatment of acute promyelocytic leukemia with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab ozogamicin. J Clin Oncol. 2009;27(4):504–510.
  • Abaza Y, Kantarjian H, Garcia-Manero G, et al. Long-term outcome of acute promyelocytic leukemia treated with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab. Blood. 2017;129(10):1275–1283.
  • Park J, Jurcic JG, Rosenblat T, et al. Emerging new approaches for the treatment of acute promyelocytic leukemia. Ther Adv Hematol. 2011;2(5):335–352.
  • Burnett AK, Grimwade D, Solomon E, et al. Presenting white blood cell count and kinetics of molecular remission predict prognosis in acute promyelocytic leukemia treated with all-trans retinoic acid: result of the randomized MRC trial. Blood. 1999;93(12):4131–4143.
  • Sanz MA, Lo Coco F, Martín G, et al. Definition of relapse risk and role of nonanthracycline drugs for consolidation in patients with acute promyelocytic leukemia: a joint study of the PETHEMA and GIMEMA cooperative groups. Blood. 2000;96(4):1247–1253.
  • Lo Cocco F, Diverio D, Avvisati G, et al. Therapy of molecular relapse in acute promyelocytic leukemia. Blood. 1999;94(7):2225–2229.
  • Esteve J, Escoda L, Martín G, et al. Outcome of patients with acute promyelocytic leukemia failing to front-line treatment with all-trans retinoic acid and anthracycline-based chemotherapy (PETHEMA protocols LPA96 and LPA99): benefit of an early intervention. Leukemia. 2007;21(3):446–452.
  • Platzbecker U, Avvisati G, Cicconi L, et al. Improved outcomes with retinoic acid and arsenic trioxide compared with retinoic acid and chemotherapy in non-high-risk acute promyelocytic leukemia: final results of the randomized Italian–German APL0406 trial. J Clin Oncol. 2017;35(6):605–612.
  • Cicconi L, Breccia M, Franceschini L, et al. Prolonged treatment with arsenic trioxide (ATO) and all-trans-retinoic acid (ATRA) for relapsed acute promyelocytic leukemia previously treated with ATRA and chemotherapy. Ann Hematol. 2018;97(10):1797–1802.
  • Estey E, Garcia-Manero G, Ferrajoli A, et al. Use of all-trans retinoic acid plus arsenic trioxide as an alternative to chemotherapy in untreated acute promyelocytic leukemia. Blood. 2006;107(9):3469–3473.
  • Iland HJ, Collins M, Bradstock K, et al. Use of arsenic trioxide in remission induction and consolidation therapy for acute promyelocytic leukaemia in the Australasian leukaemia and lymphoma group (ALLG) APML4 study: a non-randomised phase 2 trial. Lancet Haematol. 2015;2(9):e357-66–e366.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.